AbbVie’s new multiple myeloma bispecific posts 74% response rate versus 45.7% with standard therapy
AbbVie’s Phase 3 CERVINO trial met both primary endpoints as etentamig achieved a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.